Published on:
Selumetinib is the first drug approved for pediatric patients aged 2 years or older with neurofibromatosis type 1 (NF1), a rare disfiguring disease.
Read more Source: jamanetwork.com
Published on:
Selumetinib is the first drug approved for pediatric patients aged 2 years or older with neurofibromatosis type 1 (NF1), a rare disfiguring disease.
Read more Source: jamanetwork.com